Literature DB >> 18072270

Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas.

Roberta Sestini1, Costanza Bacci, Aldesia Provenzano, Maurizio Genuardi, Laura Papi.   

Abstract

Schwannomatosis is characterized by the onset of multiple intracranial, spinal, or peripheral schwannomas, without involvement of the vestibular nerve, which is instead pathognomonic of neurofibromatosis type 2 (NF2). Recently, a schwannomatosis family with a germline mutation of the SMARCB1 gene on chromosome 22 has been described. We report on the molecular analysis of the SMARCB1 and NF2 genes in a series of 21 patients with schwannomatosis and in eight schwannomatosis-associated tumors from four different patients. A novel germline SMARCB1 mutation was found in one patient; inactivating somatic mutations of NF2, associated with loss of heterozygosity (LOH) of 22q, were found in two schwannomas of this patient. This is the second report of a germline SMARCB1 mutation in patients affected by schwannomatosis and the first report of SMARCB1 mutations associated with somatic NF2 mutations in schwannomatosis-associated tumors. The latter observation suggests that a four-hit mechanism involving the SMARCB1 and NF2 genes may be implicated in schwannomatosis-related tumorigenesis. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18072270     DOI: 10.1002/humu.20679

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  50 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

Review 2.  Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature.

Authors:  Ana-Maria Vranceanu; Vanessa L Merker; Elyse R Park; Scott R Plotkin
Journal:  J Neurooncol       Date:  2015-02-07       Impact factor: 4.130

3.  Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.

Authors:  Camille Louvrier; Eric Pasmant; Audrey Briand-Suleau; Joëlle Cohen; Patrick Nitschké; Juliette Nectoux; Lucie Orhant; Cécile Zordan; Cyril Goizet; Stéphane Goutagny; Dominique Lallemand; Michel Vidaud; Dominique Vidaud; Michel Kalamarides; Béatrice Parfait
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

4.  Clinical response to bevacizumab in schwannomatosis.

Authors:  Jaishri Blakeley; Karisa C Schreck; D Gareth Evans; Bruce R Korf; David Zagzag; Matthias A Karajannis; Amanda L Bergner; Allan J Belzberg
Journal:  Neurology       Date:  2014-10-22       Impact factor: 9.910

5.  Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.

Authors:  Scott R Plotkin; Jaishri O Blakeley; D Gareth Evans; C Oliver Hanemann; Theo J M Hulsebos; Kim Hunter-Schaedle; Ganjam V Kalpana; Bruce Korf; Ludwine Messiaen; Laura Papi; Nancy Ratner; Larry S Sherman; Miriam J Smith; Anat O Stemmer-Rachamimov; Jeremie Vitte; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2013-02-07       Impact factor: 2.802

Review 6.  Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromes.

Authors:  Fausto J Rodriguez; Constantine A Stratakis; D Gareth Evans
Journal:  Acta Neuropathol       Date:  2011-12-31       Impact factor: 17.088

7.  CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.

Authors:  Brigitte C Widemann; Maria T Acosta; Sylvia Ammoun; Allan J Belzberg; Andre Bernards; Jaishri Blakeley; Antony Bretscher; Karen Cichowski; D Wade Clapp; Eva Dombi; Gareth D Evans; Rosalie Ferner; Cristina Fernandez-Valle; Michael J Fisher; Marco Giovannini; David H Gutmann; C Oliver Hanemann; Robert Hennigan; Susan Huson; David Ingram; Joe Kissil; Bruce R Korf; Eric Legius; Roger J Packer; Andrea I McClatchey; Frank McCormick; Kathryn North; Minja Pehrsson; Scott R Plotkin; Vijaya Ramesh; Nancy Ratner; Susann Schirmer; Larry Sherman; Elizabeth Schorry; David Stevenson; Douglas R Stewart; Nicole Ullrich; Annette C Bakker; Helen Morrison
Journal:  Am J Med Genet A       Date:  2014-01-17       Impact factor: 2.802

8.  Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis.

Authors:  Miriam J Smith; Andrew J Wallace; Naomi L Bowers; Cecilie F Rustad; C Geoff Woods; Guy D Leschziner; Rosalie E Ferner; D Gareth R Evans
Journal:  Neurogenetics       Date:  2012-03-22       Impact factor: 2.660

9.  Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri.

Authors:  Pepijn van den Munckhof; Imke Christiaans; Susan B Kenter; Frank Baas; Theo J M Hulsebos
Journal:  Neurogenetics       Date:  2011-10-26       Impact factor: 2.660

10.  Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas.

Authors:  Arkadiusz Piotrowski; Jing Xie; Ying F Liu; Andrzej B Poplawski; Alicia R Gomes; Piotr Madanecki; Chuanhua Fu; Michael R Crowley; David K Crossman; Linlea Armstrong; Dusica Babovic-Vuksanovic; Amanda Bergner; Jaishri O Blakeley; Andrea L Blumenthal; Molly S Daniels; Howard Feit; Kathy Gardner; Stephanie Hurst; Christine Kobelka; Chung Lee; Rebecca Nagy; Katherine A Rauen; John M Slopis; Pim Suwannarat; Judith A Westman; Andrea Zanko; Bruce R Korf; Ludwine M Messiaen
Journal:  Nat Genet       Date:  2013-12-22       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.